Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168846 | 0.86 | — | — | |
| SCHEMBL15987254 | 0.84 | CES2 (0.40) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL14327717 | 0.82 | — | — | |
| SCHEMBL11924597 | 0.82 | — | — | |
| SCHEMBL16330210 | 0.82 | TSHR (0.38) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL16327878 | 0.80 | KDM4E (0.32) | KDM4EMAPK1HIF1ATSHRPAOX | |
| SCHEMBL15674861 | 0.80 | ALDH1A1 (0.48) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL29971922 | 0.80 | KDM4E (0.36) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL1832048 | 0.79 | — | — | |
| SCHEMBL13780277 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0762901-B9 | TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING | CIS BIO INT (FR) | 2007-01-17 | — | — | EP | claimed |
| EP-0762901-B1 | TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING | BERLEX INC (US) | 2006-04-19 | — | — | EP | claimed |
| CN-1087630-C | Radiolabeled compounds for imaging thrombi | DIATECH INC (US) | 2002-07-17 | — | — | CN | claimed |
| US-6074627-A | STABLE COMPLEX | DIATIDE, INC. (US) | 2000-06-13 | — | — | US | claimed |
| US-5997844-A | Technetium-99m labeled peptides for imaging | DIATIDE, INC. (US) | 1999-12-07 | — | — | US | claimed |
| US-5830856-A | RADIOLABELED SCINTIGRAPHIC IMAGING | DIATIDE, INC. (US) | 1998-11-03 | — | — | US | claimed |
| EP-0804481-A1 | SOMATOSTATIN DERIVATIVES AND THEIR RADIOLABELLED PRODUCTS | Diatide, Inc. (US) | 1997-11-05 | — | — | EP | claimed |
| CN-1154071-A | Radiolabeled compounds for imaging thrombi | DIATECH INC (US) | 1997-07-09 | — | — | CN | claimed |
| EP-0775160-A1 | CYCLIC HEXAPEPTIDE SOMATOSTATIN ANALOGUES | DIATECH, INC. (US) | 1997-05-28 | — | — | EP | claimed |
| WO-1996004308-A1 | CYCLIC HEXAPEPTIDE SOMATOSTATIN ANALOGUES | DIATECH, INC. (US) | 1996-02-15 | — | — | WO | claimed |
| US-4292428-A | ANTIBIOTICS; EASILY HYDROLYZED ESTERS AND ETHERS | HOFFMANN-LA ROCHE INC. (US) | 1981-09-29 | — | — | US | claimed |
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | CITY OF HOPE (US) | 2026-04-28 | — | — | US | disclosed |
| US-12611461-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-16 | — | — | US | disclosed |
| US-12589162-B2 | Trans-cyclooctene prodrug of monomethyl auristatin E | TAMBO, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-0029966-A2 | Cephalosporin derivatives, preparations thereof, and pharmaceuticals compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-06-10 | — | — | EP | disclosed |
| EP-0008372-A1 | Easily hydrolysable esters and ethers of cephalosporines, their preparation and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-03-05 | — | — | EP | disclosed |
| EP-0005830-A1 | Cephalosporin derivatives, their preparation and the corresponding pharmaceutical compositions | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-12-12 | — | — | EP | disclosed |
| US-4076662-A | Modified aminoplast compositions | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1978-02-28 | — | — | US | disclosed |
| US-4076662-A | Modified aminoplast compositions | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589162-B2 | Trans-cyclooctene prodrug of monomethyl auristatin E | AURKC, AURKA, QPCT | KDM4E 919/4885MAPK1 2685/4885HIF1A 3814/4885 |
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | STAT3, NSUN2, STAT1 | KDM4E 2625/4885MAPK1 1692/4885HIF1A 2609/4885 |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | PTPN5, PTPN1, PTPN3 | KDM4E 300/4885MAPK1 191/4885HIF1A 3419/4885 |
| US-12611461-B2 | Bioorthogonal compositions | ACVRL1, FCGR2A, CHIT1 | KDM4E 3869/4885MAPK1 3218/4885HIF1A 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.